MedWatch

Zealand Pharma planned for success

Despite great progress of its clinical pipeline and the initiation of two phase III studies, the Danish biotech company Zealand Pharma maintains its guidance for the level of costs in 2017. “We planned for success from the beginning of the year,” says CEO Britt Meelby Jensen.

Foto: Zealand Pharma PR

The presentation of Zealand Pharma’s financial results for the first half and second quarter of 2017 did not bring many surprises.

The company had already announced its royalty income from partner Sanofi prior to the publication of the report, and both revenue and net loss came in largely as expected.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier